PHÂN TÍCH THỰC TRẠNG KÊ ĐƠN TƯƠNG TÁC THUỐC – BỆNH VỚI CÁC THUỐC TIM MẠCH – NỘI TIẾT TẠI BỆNH VIỆN ĐA KHOA VÂN ĐÌNH NĂM 2025

Abstract

Objective: To develop a list and analyze the current situation of prescribing contraindicated drug–disease interactions involving cardiovascular and endocrine medications at Van Dinh General Hospital in 2025. Method: Cross-sectional descriptive study. Results: From the 2025 drug formulary of Van Dinh General Hospital, the research team selected 31 active substances for analysis. After searching and synthesizing information from various databases, excluding pairs involving acute diseases, conditions requiring mandatory medical treatment, and diseases without confirmed ICD codes, the study identified 59 pairs of contraindicated drug–disease interactions related to cardiovascular and endocrine medications. Based on the established list, the study screened 7,674 prescriptions with a total of 39,289 medication-use instances (excluding repeated use in hospitalized patients) and identified 35 prescriptions containing at least one drug–disease interaction. Patients identified with contraindicated drug–disease interactions were generally older, had multiple comorbidities, and were taking multiple concurrent medications. A total of 7 active substances were associated with 47 contraindicated drug–disease pairs. Cardiovascular drugs identified in interaction-containing prescriptions included trimetazidine and nifedipine (accounting for 8.51% and 6.38% of all interaction pairs, respectively). Diuretics included hydrochlorothiazide and spironolactone (34.04% and 2.13%, respectively). Antidiabetic drugs associated with interactions included gliclazide, metformin, and glimepiride (27.66%, 19.15%, and 2.13%, respectively). The most commonly observed contraindicated drug–disease pair involved severe renal impairment with creatinine clearance <30 mL/min (91.49% of all interaction pairs).